As a leading healthcare provider, we recognize that our conduct must be beyond reproach when it comes to Ethics. In every aspect of our activities from how we conduct research and clinical trials to the way we treat our partners, customers and colleagues, we strive to attain the highest standards of scientific, business and personal integrity through our commitment to transparency, openness and fairness. At Sanofi, we know that acting ethically and responsibly benefits patients.
Code of Ethics and Business Code of Conduct
To ensure that our daily work is in the best interest of patients and the community, we follow the Sanofi Code of Ethics as well as the US Supplement in the United States. Our employees adhere to these codes because the way we conduct business, how we approach innovation and research & development, and how we produce and commercialize our products is just as important as the products and services themselves.
Sanofi strives to continuously improve our ethical standing and to incorporate good ethical practices into our day-to-day work. The Global Code of Ethics and the US Supplement are designed for use by our employees (full-time and part-time) and contractors to help them understand the ethical and business expectations to which they must adhere while conducting business on behalf of our company. Training and educational sessions are held on a regular basis. On a yearly basis, employees acknowledge their responsibility and commitment to carry out our business practices consistent with these standards. Any employee who violates these standards is subject to appropriate disciplinary action.
Employees and contractors are required to report potential violation(s) of the Code of Ethics and the US Supplement immediately. The Code prohibits retaliation against anyone who reports a suspected violation. Several reporting avenues are in place.
For more information about these Codes of Business Conduct:
- Click here to access the Sanofi Code of Ethics
- Click here to access the Sanofi Code of Ethics – US Supplement
Scientific and medical research is an essential part of preventing and combating disease. It demands transparency toward stakeholders, respect for individuals and compliance with regulations. It therefore involves far-reaching ethical considerations.
Clinical Trials & Animal Welfare
Sanofi sponsors clinical trials through its pharmaceutical and vaccine businesses as well as ventures with government organizations, other pharmaceutical companies and biotech firms. All clinical trials are conducted in compliance with strict ethical and quality regulations including those issued by the FDA.
Click here to find out more information about Clinical Trials at Sanofi.
Sanofi US follows the Sanofi Charter for the Humane Care and Use of Laboratory Animals. This charter, established in 2006, outlines a set of principles that are applied globally to ensure the highest standard of animal care and use. Sanofi also adheres to the 3R’s principle, which is the Reduction, Refinement, and/or Replacement of animals in research whenever possible.
Click here to find out more information about Animal Welfare at Sanofi.
As a signatory to the UN Global Compact, Sanofi pledges to support and apply its fundamental principles in the areas of human rights, working conditions, the environment and the fight against corruption. At Sanofi US, we seek to engage with all of our suppliers to share our company policies in these areas.
Respect for human rights forms the foundation upon which our corporate social responsibility policy is built. When we deal with suppliers, we are governed by local legislation, our internal policies and our standards in terms of human rights, labor, environment, and ethical conduct.
Sanofi’s Corporate Code of Ethics and Supplier Code of Conduct are based on the UN Global Compact principles, and elements also are derived from the Universal Declaration of Human Rights, the International Labour Organization's Declaration on Fundamental Principles and Rights at Work (ILO), and the Rio Declaration on Environment and Development and the United Nations Convention Against Corruption. In 2007, Sanofi became one of the founding members of the French organization EDH (Entreprises pour les Droits de l’Homme—Businesses for Human Rights). The EDH’s goal is to help make the Universal Declaration of Human Rights principles an integral part of company operations through the following initiatives:
- Discussing and sharing best practices with other companies
- Working together with key stakeholders in human rights, to develop solutions with the goal of improving these practices
- Participating in discussions in France and other countries on how to incorporate human rights into company management systems and tools
In 2010, in collaboration with EDH, Sanofi took part in developing a new inter-company human rights training tool for senior executives of the various EDH member companies. Through this initiative, Sanofi can introduce this awareness-raising tool which uses materials developed with EDH that are specifically tailored to the pharmaceutical industry.
Sanofi is in an ongoing process of self-assessing its human rights practices at the corporate level by using the Business and Human Rights Matrix of the Business Leaders Initiative for Human Rights (BLIHR). In 2010, we established an inventory of our practices at the global and regional levels, thus identifying areas for improvement. Within the framework of human rights, all Sanofi businesses around the world, including the U.S., have implemented the Sanofi Responsible Procurement program that is based on the Sanofi Supplier Code of Conduct.
Sanofi’s Policy on Responsible Procurement and Disclosure Pursuant to California Transparency in Supply Chains Act
Sanofi US’s standard Request for Proposals (RFP) attaches the Sanofi Supplier Code of Conduct as well as a questionnaire that includes inquiries pertaining to potential suppliers’ economic, social and environmental performance and a statement advising potential suppliers that they are expected to be compliant with the Sanofi Supplier Code of Conduct. In addition, Sanofi US’s standard Master Services agreement that may be provided to potential suppliers includes a provision requiring certification of compliance, to the extent legally required, with prohibitions against human trafficking and forced labor, including with the applicable local laws of the country or countries in which they do business as well as the pertinent principles established by the U.N. and ILO.
All suppliers that are considered a business or procurement risk (including those in high-risk countries) as well as long-term suppliers also are asked to complete supplier assessment questionnaires. The questionnaires similarly include inquiries pertaining to the suppliers’ economic, social and environmental performance and a statement advising suppliers that they are expected to be compliant with the Sanofi Supplier Code of Conduct (which includes prohibitions on human trafficking and forced labor). If certain questions are not answered completely, Sanofi Procurement representatives may ask the suppliers for more information and their participation in a face-to-face interview. Additionally, based on the quality of the responses, Procurement may choose to conduct a third party supplier audit.
In cases where potential issues as to particular suppliers are identified, the company may take suitable action dependent on the circumstances presented, including, for example, it may work with a supplier to develop an improvement plan, or may decline to continue the supplier relationship or may take other action. In addition, all the information captured during the reviews is incorporated into a corporate database. In this way, Sanofi affiliates around the world can obtain information about those suppliers that have been reviewed and their status reported.
The foregoing disclosures are made pursuant to the California Transparency in Supply Chains Act.